SAM
RARE icon

Shell Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Shell Asset Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$16K Sell
529
-924
-64% -$27.7K ﹤0.01% 1067
2025
Q2 		$53K Sell
1,453
-694
-32% -$25K ﹤0.01% 1136
2025
Q1 		$78K Sell
2,147
-93
-4% -$3.87K ﹤0.01% 1063
2024
Q4 		$94K Sell
2,240
-15
-0.7% -$744 ﹤0.01% 1058
2024
Q3 		$125K Buy
+2,255
New +$115K 0.01% 994
2024
Q1 		$98K Sell
2,386
-247
-9% -$11.7K ﹤0.01% 1030
2023
Q4 		$126K Sell
2,633
-792
-23% -$30.7K 0.01% 1003
2023
Q3 		$122K Sell
3,425
-54
-2% -$2.14K 0.01% 1039
2023
Q2 		$160K Sell
3,479
-20
-0.6% -$928 0.01% 992
2023
Q1 		$140K Sell
3,499
-12
-0.3% -$515 0.01% 1030
2022
Q4 		$163K Sell
3,511
-713
-17% -$28K 0.01% 1024
2022
Q3 		$175K Sell
4,224
-1,105
-21% -$56.8K 0.01% 1056
2022
Q2 		$318K Buy
5,329
+8
+0.2% +$492 0.01% 949
2022
Q1 		$386K Sell
5,321
-787
-13% -$54.8K 0.01% 936
2021
Q4 		$514K Buy
6,108
+21
+0.3% +$1.71K 0.01% 888
2021
Q3 		$549K Sell
6,087
-260
-4% -$23.5K 0.01% 823
2021
Q2 		$605K Buy
6,347
+340
+6% +$35.4K 0.01% 827
2021
Q1 		$684K Buy
6,007
+1,840
+44% +$250K 0.01% 712
2020
Q4 		$577K Sell
4,167
-681
-14% -$80.8K 0.01% 732
2020
Q3 		$398K Hold
4,848
– – 0.01% 779
2020
Q2 		$379K Sell
4,848
-82
-2% -$5.43K 0.01% 788
2020
Q1 		$219K Sell
4,930
-75
-1% -$3.89K 0.01% 982
2019
Q4 		$214K Sell
5,005
-135
-3% -$5.57K ﹤0.01% 1124
2019
Q3 		$220K Sell
5,140
-44
-0.8% -$2.39K 0.01% 1111
2019
Q2 		$329K Sell
5,184
-117
-2% -$7.45K 0.01% 1046
2019
Q1 		$368K Hold
5,301
– – 0.01% 1012
2018
Q4 		$230K Sell
5,301
-400
-7% -$21.9K 0.01% 1022
2018
Q3 		$435K Buy
+5,701
New +$464K 0.01% 997

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Shell Asset Management's RARE Position: Q3 2025 in Review

Shell Asset Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 64% in Q3 2025, selling an estimated $27.7K and leaving 529 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #1067.

Shell Asset Management first reported a position in RARE in Q3 2018 and has held it in 28 quarters since. The position peaked at $684K in Q1 2021. 303 funds tracked by Wall St. Rank hold RARE as of Q3 2025.

  • Shell Asset Management held 529 shares of Ultragenyx Pharmaceutical worth $16K as of Q3 2025.
  • Shell Asset Management sold 924 Ultragenyx Pharmaceutical shares in Q3 2025, an estimated $27.7K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Shell Asset Management's portfolio in Q3 2025, its #1067 holding.
  • Shell Asset Management first reported a position in Ultragenyx Pharmaceutical in Q3 2018 and has held it in 28 quarters since.
  • Shell Asset Management's Ultragenyx Pharmaceutical position peaked at $684K in Q1 2021.
  • 303 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2025.

Based on Shell Asset Management's 13F filing for Q3 2025, filed 7 Nov 2025.